Cited by 391Genetic Syndromes and ImprintingGenetics and Neurodevelopmental DisordersEpigenetics and DNA Methylation

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons

Open access

Huang, Hsien-Sung, Allen, John A., Mabb, Angela M., King, Ian F., Miriyala, Jayalakshmi, Taylor-Blake, Bonnie, Sciaky, Noah, Dutton, J. Walter, Lee, Hyeong-Min, Chen, Xin, Jin, Jian, Bridges, Arlene S., Zylka, Mark J., Roth, Bryan L., Philpot, Benjamin D.·2012·Nature

DOI 10.1038/nature10726PMC PMC3257422

Open this paper in CoChat — free account

Abstract

Angelman syndrome is a severe neurodevelopmental disorder caused by deletion or mutation of the maternal allele of the ubiquitin protein ligase E3A (UBE3A). In neurons, the paternal allele of UBE3A is intact but epigenetically silenced, raising the possibility that Angelman syndrome could be treated by activating this silenced allele to restore functional UBE3A protein. Using an unbiased, high-content screen in primary cortical neurons from mice, we identify twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal Ube3a allele. These drugs included topotecan, irinotecan, etoposide and dexrazoxane (ICRF-187). At nanomolar concentrations, topotecan upregulated catalytically active UBE3A in neurons from maternal Ube3a-null mice. Topotecan concomitantly downregulated expression of the Ube3a antisense transcript that overlaps the paternal copy of Ube3a. These results indicate that topotecan unsilences Ube3a in cis by reducing transcription of an imprinted antisense RNA. When administered in vivo, topotecan unsilenced the paternal Ube3a allele in several regions of the nervous system, including neurons in the hippocampus, neocortex, striatum, cerebellum and spinal cord. Paternal expression of Ube3a remained elevated in a subset of spinal cord neurons for at least 12 weeks after cessation of topotecan treatment, indicating that transient topoisomerase inhibition can have enduring effects on gene expression. Although potential off-target effects remain to be investigated, our findings suggest a therapeutic strategy for reactivating the functional but dormant allele of Ube3a in patients with Angelman syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature10726

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Image processing with ImageJ
Abràmoff, M. D., Magalhães, P. J., & Ram, S. J. (2004) · Utrecht University Repository (Utrecht University) · Cited by 11,816
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1977 · Cited by 2,362
Stability and flexibility of epigenetic gene regulation in mammalian development
Reik, W. (2007) · Nature · doi:10.1038/nature05918 · Cited by 1,963 · cited 1×
“Genomic imprinting is thought to be established only during prescribed germline and embryonic periods of development and imprinted genes typically remain epigenetically regulated throughout lif”
Background
UBE3A/E6-AP mutations cause Angelman syndrome
Kishino, T., Lalande, M., & Wagstaff, J. E. (1997) · Nature Genetics · doi:10.1038/ng0197-70 · Cited by 1,304
Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascade
Scheffner, M., Nuber, U. A., & Huibregtse, J. M. (1995) · Nature · doi:10.1038/373081a0 · Cited by 1,017
CellProfiler™: Free, Versatile Software for Automated Biological Image Analysis
Lamprecht, M. R., Sabatini, D. M., & Carpenter, A. E. (2007) · BioTechniques · doi:10.2144/000112257 · Cited by 880
De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome
Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R. H., Jiang, Y., Benton, C. S., Rommens, J. M., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0197-74 · Cited by 858
Mutation of the Angelman Ubiquitin Ligase in Mice Causes Increased Cytoplasmic p53 and Deficits of Contextual Learning and Long-Term Potentiation
Jiang, Y.-H., Armstrong, D., Albrecht, U., Atkins, C. M., Noebels, J. L., Eichele, G., Sweatt, J. D., & Beaudet, A. L. (1998) · Neuron · doi:10.1016/s0896-6273(00)80596-6 · Cited by 852
Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons
Albrecht, U., Sutcliffe, J. S., Cattanach, B. M., BEECHEY, C. V., Armstrong, D. L., Gregor Eichele, C., & Beaudet, A. L. (1997) · Nature Genetics · doi:10.1038/ng0997-75 · Cited by 587
Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism
Nakatani, J., Tamada, K., Hatanaka, F., Ise, S., Ohta, H., Inoue, K., Tomonaga, S., Watanabe, Y., Chung, Y. J., Banerjee, R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.024 · Cited by 482

Flagged first, then by citations

Show all 38 references

Sorted by citations

Items 101–200 of 391

CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review
Syding, L. A., Nickl, P., Kašpárek, P., & Sedláček, R. (2020) · Cells · doi:10.3390/cells9040993 · Cited by 65
An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome
Grieco, J. C., Ciarlone, S. L., Gieron-Korthals, M. A., Schoenberg, M. R., Smith, A., Philpot, R. M., Heussler, H., Banko, J. L., & Weeber, E. J. (2014) · BMC Neurology · doi:10.1186/s12883-014-0232-x · Cited by 60
RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases
Germain, N. D., Chung, W. K., & Sarmiere, P. D. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101148 · Cited by 60
Topoisomerase I in Human Disease Pathogenesis and Treatments
Li, M., & Liu, Y. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.02.004 · Cited by 62
Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome
Berg, E. L., Pride, M. C., Petkova, S. P., Lee, R. D., Copping, N. A., Shen, Y., Adhikari, A., Fenton, T. A., Pedersen, L. R., Noakes, L. S., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0720-2 · Cited by 61
Activity-Dependent Arc Expression and Homeostatic Synaptic Plasticity Are Altered in Neurons from a Mouse Model of Angelman Syndrome
Pastuzyn, E. D., & Shepherd, J. D. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00234 · Cited by 57
Dynamic Effects of Topoisomerase I Inhibition on R-Loops and Short Transcripts at Active Promoters
Marinello, J., Bertoncini, S., Aloisi, I., Cristini, A., Tagliazucchi, G. M., Forcato, M., Sordet, O., & Capranico, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147053 · Cited by 56
Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor
Ng, K., Mok, P. Y., Butler, A. W., Ho, J. C.-Y., Choi, S. W., Lee, Y.-K., Lai, W., Au, K., Lau, Y., Wong, L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019847 · Cited by 57
Ca2+/Calmodulin-dependent Protein Kinase IIα (αCaMKII) Controls the Activity of the Dopamine Transporter
Steinkellner, T., Yang, J., Montgomery, T., Chen, W., Winkler, M.-T., Sučić, S., Lübec, G., Freissmuth, M., Elgersma, Y., Sitte, H. H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.367219 · Cited by 56
UBE3A reinstatement as a disease‐modifying therapy for Angelman syndrome
Elgersma, Y., & Sonzogni, M. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14831 · Cited by 60
Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes
Sonzogni, M., Hakonen, J., Kleijn, M. B., Silva-Santos, S., Judson, M. C., Philpot, B. D., van Woerden, G. M., & Elgersma, Y. (2019) · Molecular Autism · doi:10.1186/s13229-019-0277-1 · Cited by 57
Self-citation
Transcription Poisoning by Topoisomerase I Is Controlled by Gene Length, Splice Sites, and miR-142-3p
Solier, S., Ryan, M., Martin, S. E., Varma, S., Kohn, K. W., Liu, H., Zeebèrg, B. R., & Pommier, Y. G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3504 · Cited by 54
Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice
Gu, B., Carstens, K. E., Judson, M. C., Tuite-Dalton, K. A., Rougié, M., Clark, E. P., Dudek, S. M., & Philpot, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120816 · Cited by 55
Self-citation
Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence Reporter
Hasson, S. A., Fogel, A. I., Wang, C., MacArthur, R., Guha, R., Heman-Ackah, S. M., Martin, S. E., Youle, R. J., & Inglese, J. (2015) · ACS Chemical Biology · doi:10.1021/cb5010417 · Cited by 53
Epigenetic therapy of Prader–Willi syndrome
Kim, Y., Wang, S. E., & Jiang, Y. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.012 · Cited by 53
Epigenetic Mechanisms in Autism Spectrum Disorder
Zhubi, A., Cook, E. H., Guidotti, A., & Grayson, D. R. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801311-3.00006-8 · Cited by 56
Understanding the Pathogenesis of Angelman Syndrome through Animal Models
Jana, N. R. (2012) · Neural Plasticity · doi:10.1155/2012/710943 · Cited by 54
The Angelman Syndrome Protein Ube3a/E6AP Is Required for Golgi Acidification and Surface Protein Sialylation
Condon, K. H., Ho, J., Robinson, C. G., Hanus, C., & Ehlers, M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1930-11.2013 · Cited by 51
Topoisomerase 1 Regulates Gene Expression in Neurons through Cleavage Complex-Dependent and -Independent Mechanisms
Mabb, A. M., Simon, J. M., King, I. F. G., Lee, H.-M., An, L., Philpot, B. D., & Zylka, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156439 · Cited by 52
Self-citation
Angelman syndrome: Current and emerging therapies in 2016
Tan, W., & Bird, L. M. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31536 · Cited by 52
Topoisomerase 1 inhibition reversibly impairs synaptic function
Mabb, A. M., Kullmann, P. H. M., Twomey, M. A., Miriyala, J., Philpot, B. D., & Zylka, M. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413204111 · Cited by 49
Self-citation
Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells
Adhikari, A., Copping, N. A., Beegle, J. R., Cameron, D. L., Deng, P., O’Geen, H., Segal, D. J., Fink, K. D., Silverman, J. L., & Anderson, J. S. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab104 · Cited by 52
Epigenetic Basis of Neuronal and Synaptic Plasticity
Karpova, N. N., Sales, A. J., & Joca, S. R. L. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160414124628 · Cited by 51
Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research
Brown, D. G., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00797 · Cited by 47
Therapies in preclinical and clinical development for Angelman syndrome
Markati, T., Duis, J. B., & Servais, L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1939674 · Cited by 48
The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial
Hipp, J. F., Bacino, C. A., Bird, L. M., Bruenig-Traebert, I., Chan, D., de Wit, M. Y., da Fontoura, P. P., Hooper, G., Jagasia, R., Krishnan, M. L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03784-7 · Cited by 47
The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders
Owais, A., Mishra, R. K., & Kiyokawa, H. (2020) · Cancers · doi:10.3390/cancers12082108 · Cited by 48
Detection of Azoxystrobin Fungicide and Metabolite Azoxystrobin-Acid in Pregnant Women and Children, Estimation of Daily Intake, and Evaluation of Placental and Lactational Transfer in Mice
Hu, W., Liu, C.-W., Jiménez, J. A., McCoy, E. S., Hsiao, Y.-C., Lin, W., Engel, S. M., Lü, K., & Zylka, M. J. (2022) · Environmental Health Perspectives · doi:10.1289/ehp9808 · Cited by 46
Self-citation
Epigenetic mechanisms of gene expression regulation in neurological diseases
Goś, M. (2013) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2013-1919 · Cited by 45
Delta power robustly predicts cognitive function in Angelman syndrome
Ostrowski, L. M., Spencer, E. R., Bird, L. M., Thibert, R. L., Komorowski, R. W., Kramer, M., & Chu, C. J. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51385 · Cited by 45
Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice
Judson, M. C., Shyng, C., Simon, J. M., Davis, C. R., Punt, A. M., Salmon, M. T., Miller, N. W., Ritola, K., Elgersma, Y., Amaral, D. G., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144712 · Cited by 46
Self-citation
Topoisomerase 1B poisons: Over a half‐century of drug leads, clinical candidates, and serendipitous discoveries
Cinelli, M. A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21546 · Cited by 44
R-loop: an emerging regulator of chromatin dynamics
Al‐Hadid, Q., & Yang, Y. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw052 · Cited by 43
The Top1 paradox: Friend and foe of the eukaryotic genome
Kim, N., & Jinks-Robertson, S. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.06.005 · Cited by 42
Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice
Judson, M. C., Burette, A. C., Thaxton, C., Pribisko, A. L., Shen, M. D., Rumple, A., Cid, W. A. D., Paniagua, B., Styner, M. A., Weinberg, R. J., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0037-17.2017 · Cited by 42
Self-citation
Apparent bias toward long gene misregulation in MeCP2 syndromes disappears after controlling for baseline variations
Raman, A. T., Pohodich, A. E., Wan, Y., Yalamanchili, H. K., Lowry, W. E., Zoghbi, H. Y., & Liu, Z. (2018) · Nature Communications · doi:10.1038/s41467-018-05627-1 · Cited by 42
CIM6P / IGF ‐2 Receptor Ligands Reverse Deficits in Angelman Syndrome Model Mice
Cruz, E., Descalzi, G., Steinmetz, A. B., Scharfman, H. E., Katzman, A. C., & Alberini, C. M. (2020) · Autism Research · doi:10.1002/aur.2418 · Cited by 45
Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome
Sonzogni, M., Zhai, P., Mientjes, E., van Woerden, G. M., & Elgersma, Y. (2020) · Molecular Autism · doi:10.1186/s13229-020-00376-9 · Cited by 42
A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice
Li, J., Shen, Z., Liu, Y., Yan, Z., Liu, Y., Lin, X., Tang, J., Lv, R., Geng, G., Xiong, Z., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.015 · Cited by 40
Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome
Copping, N. A., McTighe, S. M., Fink, K. D., & Silverman, J. L. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01082-x · Cited by 42
Autism and Epilepsy
Capal, J. K., & Jeste, S. (2024) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2024.01.004 · Cited by 38
Snx14 Regulates Neuronal Excitability, Promotes Synaptic Transmission, and Is Imprinted in the Brain of Mice
Huang, H., Yoon, B.-J., Brooks, S., Bakal, R. S., Wallace, J. B., Larsen, R. S., Wallace, M. L., Han, J. E., Chung, E., Zylka, M. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098383 · Cited by 38
Self-citation
Gene-targeting pharmaceuticals for single-gene disorders
Beaudet, A. L., & Meng, L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv476 · Cited by 38
Epigenetic Mistakes in Neurodevelopmental Disorders
Mastrototaro, G., Zaghi, M., & Sessa, A. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0900-6 · Cited by 38
iPSC-based drug screening for Huntington׳s disease
Zhang, N., Bailus, B. J., Ring, K. L., & Ellerby, L. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.020 · Cited by 37
Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome
Lee, D., Chen, W., Kaku, H. N., Zhuo, X., Chao, E. S., Soriano, A., Kuncheria, A., Flores, S., Kim, J. H., Rivera, A. M., et al. (2023) · eLife · doi:10.7554/elife.81892 · Cited by 36
Neural and behavioral epigenetics; what it is, and what is hype
Isles, A. R. (2014) · Genes Brain & Behavior · doi:10.1111/gbb.12184 · Cited by 36
Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy
Robert, C., Pasquier, L., Cohen, D., Fradin, M., Canitano, R., Damaj, L., Odent, S., & Tordjman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030618 · Cited by 36
Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome
Lee, H.-M., Clark, E. P., Kuijer, M. B., Cushman, M., Pommier, Y. G., & Philpot, B. D. (2018) · Molecular Autism · doi:10.1186/s13229-018-0228-2 · Cited by 36
Self-citation
The contribution of imprinted genes to neurodevelopmental and neuropsychiatric disorders
Isles, A. R. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01972-4 · Cited by 38
Five years of experience in the Epigenetics and Chromatin Clinic: what have we learned and where do we go from here?
Harris, J. R., Gao, C. W., Britton, J. F., Applegate, C. D., Bjornsson, H. T., & Fahrner, J. A. (2023) · Human Genetics · doi:10.1007/s00439-023-02537-1 · Cited by 35
Epigenetic mechanisms in diurnal cycles of metabolism and neurodevelopment
Powell, W. T., & LaSalle, J. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv234 · Cited by 36
Random and Non-Random Monoallelic Expression
Chess, A. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.85 · Cited by 36
Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology
Maheshwari, M., Shekhar, S., Singh, B. K., Jamal, I., Vatsa, N., Kumar, V., Sharma, A., & Jana, N. R. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu343 · Cited by 34
Effects of liquid cultivation on gene expression and phenotype of C. elegans
Çelen, İ., Doh, J. H., & Sabanayagam, C. R. (2018) · BMC Genomics · doi:10.1186/s12864-018-4948-7 · Cited by 34
Persistent neuronal Ube3a expression in the suprachiasmatic nucleus of Angelman syndrome model mice
Jones, K. A., Han, J. E., DeBruyne, J. P., & Philpot, B. D. (2016) · Scientific Reports · doi:10.1038/srep28238 · Cited by 34
Self-citation
Ube3a unsilencer for the potential treatment of Angelman syndrome
Vihma, H., Li, K., Welton-Arndt, A., Smith, A. L., Bettadapur, K. R., Gilmore, R. B., Gao, E. B., Cotney, J. L., Huang, H.-C., Collins, J. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49788-8 · Cited by 33
Self-citation
The ubiquitin proteasome pathway in neuropsychiatric disorders
Cheon, S., Dean, M., & Chahrour, M. H. (2018) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2018.01.012 · Cited by 34
From Multisensory Assessment to Functional Interpretation of Social Behavioral Phenotype in Transgenic Mouse Models for Autism Spectrum Disorders
Arakawa, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.592408 · Cited by 32
The role of E3 ubiquitin ligases in synapse function in the healthy and diseased brain
Kawabe, H., & Stegmüller, J. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103602 · Cited by 33
DNA Topoisomerase 1α Promotes Transcriptional Silencing of Transposable Elements through DNA Methylation and Histone Lysine 9 Dimethylation in Arabidopsis
Dinh, T. T., Gao, L., Liu, X., Li, D., Li, S., Zhao, Y., O'Leary, M. L., Le, B. H., Schmitz, R. J., Manavella, P. A., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004446 · Cited by 32
Self-citation
Dosage-sensitive genes in autism spectrum disorders: From neurobiology to therapy
Javed, S., Selliah, T., Lee, Y., & Huang, W. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.08.009 · Cited by 32
Human Cerebral Organoids Reveal Early Spatiotemporal Dynamics and Pharmacological Responses of UBE3A
Sen, D., Voulgaropoulos, A., Drobná, Z., & Keung, A. J. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.08.006 · Cited by 32
Gene Transfer Therapy for Neurodevelopmental Disorders
Özlü, C., Bailey, R. M., Sinnett, S. E., & Goodspeed, K. (2021) · Developmental Neuroscience · doi:10.1159/000515434 · Cited by 31
The Role of Long Non-coding RNAs in Human Imprinting Disorders: Prospective Therapeutic Targets
Wang, T., Li, J. J., Yang, L., Wu, M., & Ma, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730014 · Cited by 33
Toward a Broader View of Ube3a in a Mouse Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and Glial Cells
Grier, M. D., Carson, R. P., & Lagrange, A. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124649 · Cited by 29
Application of induced pluripotent stem cells in epilepsy
Hirose, S., Tanaka, Y., Shibata, M., Kimura, Y., Ishikawa, M., Higurashi, N., Yamamoto, T., Ichise, E., Chiyonobu, T., & Ishii, A. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103535 · Cited by 30
Global developmental delay and intellectual disability associated with a de novo TOP2B mutation
Lam, C., Yeung, W.-L., & Law, C. Y. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.03.022 · Cited by 30
Top2a promotes the development of social behavior via PRC2 and H3K27me3
Geng, Y., Zhang, T., Alonzo, I. G., Godar, S. C., Yates, C., Pluimer, B. R., Harrison, D. L., Nath, A. K., Yeh, J.-R. J., Drummond, I. A. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm7069 · Cited by 31
A small-molecule screen reveals novel modulators of MeCP2 and X-chromosome inactivation maintenance
Lee, H.-M., Kuijer, M. B., Blanes, N. R., Clark, E. P., Aita, M., Arjona, L. G., Kokot, A., Sciaky, N., Simon, J. M., Bhatnagar, S., et al. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09332-3 · Cited by 30
Self-citation
Maternal transcription of non-protein coding RNAs from the PWS-critical region rescues growth retardation in mice
Rozhdestvensky, T. S., Robeck, T., Galiveti, C. R., Raabe, C. A., Seeger, B., Wolters, A., Gubar, L., Brosius, J., & Skryabin, B. V. (2016) · Scientific Reports · doi:10.1038/srep20398 · Cited by 28
The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders
Bailus, B. J., & Segal, D. J. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-76 · Cited by 28
Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders
Kubota, T., Hirasawa, T., & Miyake, K. (2012) · Pharmaceuticals · doi:10.3390/ph5040369 · Cited by 27
Angelman Syndrome: Identification and Management
Bonello, D., Camilleri, F., & Calleja‐Agius, J. (2017) · Neonatal Network The Journal of Neonatal Nursing · doi:10.1891/0730-0832.36.3.142 · Cited by 27
Epigenetic and Cellular Diversity in the Brain through Allele-Specific Effects
Huang, W.-C., Bennett, K., & Gregg, C. J. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.07.005 · Cited by 27
Transferable neuronal mini-cultures to accelerate screening in primary and induced pluripotent stem cell-derived neurons
Niedringhaus, M. S., Dumitru, R., Mabb, A. M., Wang, Y., Philpot, B. D., Allbritton, N. L., & Taylor, A. M. (2015) · Scientific Reports · doi:10.1038/srep08353 · Cited by 27
Self-citation
Potential therapeutic approaches for Angelman syndrome
Bi, X., Sun, J., Ji, A. X., & Baudry, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1115837 · Cited by 27
A cross-species spatiotemporal proteomic analysis identifies UBE3A-dependent signaling pathways and targets
Pandya, N. J., Meier, S., Tyanova, S., Terrigno, M., Wang, C., Punt, A. M., Mientjes, E., Vautheny, A., Distel, B., Kremer, T., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01484-z · Cited by 28
Novel epigenetic molecular therapies for imprinting disorders
Wang, S. E., & Jiang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02208-7 · Cited by 27
Synaptic Plasticity in Mouse Models of Autism Spectrum Disorders
Chung, L., Bey, A. L., & Jiang, Y. (2012) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2012.16.6.369 · Cited by 27
Autosomal monoallelic expression: genetics of epigenetic diversity?
Savova, V., Vigneau, S., & Gimelbrant, A. A. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.09.001 · Cited by 26
Mendelian, Non-Mendelian, Multigenic Inheritance, and Epigenetics
Harel, T., Pehlivan, D., Caskey, C. T., & Lupski, J. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00001-2 · Cited by 26
DNA-intercalators Causing Rapid Re-expression of Methylated and Silenced Genes in Cancer Cells
Hossain, M. Z., Healey, M. A., Lee, C., Poh, W., Yerram, S. R., Patel, K. G., Azad, N. S., Herman, J. G., & Kern, S. E. (2013) · Oncotarget · doi:10.18632/oncotarget.863 · Cited by 25
Tubulin structure-based drug design for the development of novel 4β-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity
Zhao, W., Bai, J.-K., Li, H., Chen, T., & Ya-jie Tang, A. (2015) · Scientific Reports · doi:10.1038/srep10172 · Cited by 25
Screening in larval zebrafish reveals tissue-specific distributions of fifteen fluorescent compounds
Yao, Y., Sun, S., Fei, F., Wang, J., Wang, Y., Zhang, R., Wu, J., Liu, L., Liu, X., Cui, Z., et al. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028811 · Cited by 29
Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model
Chung, L., Bey, A. L., Towers, A. J., Cao, X., Kim, I. H., & Jiang, Y.-H. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.10.016 · Cited by 27
Parent-of-origin effects propagate through networks to shape metabolic traits
Macias-Velasco, J. F., Pierre, C. L. S., Wayhart, J. P., Yin, L., Spears, L., Miranda, M. A., Carson, C., Funai, K., Cheverud, J. M., Semenkovich, C. F., et al. (2022) · eLife · doi:10.7554/elife.72989 · Cited by 24
Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities
Leach, P. T., & Crawley, J. N. (2017) · Genes Brain & Behavior · doi:10.1111/gbb.12452 · Cited by 27
Prenatal treatment path for angelman syndrome and other neurodevelopmental disorders
Zylka, M. J. (2019) · Autism Research · doi:10.1002/aur.2203 · Cited by 24
Self-citation
Correction: Impairment of TrkB-PSD-95 Signaling in Angelman Syndrome
Cao, C., Rioult-Pedotti, M. S., Migani, P., Yu, C. J., Tiwari, R. K., Parang, K., Spaller, M. R., Goebel, D. J., & Marshall, J. (2013) · PLoS Biology · doi:10.1371/annotation/f32bc670-c9cf-4bb0-9376-cd8cfd1053c1 · Cited by 24
Chromatinopathies: insight in clinical aspects and underlying epigenetic changes
Bukowska‐Olech, E., Majchrzak‐Celińska, A., Przyborska, M., & Jamsheer, A. (2024) · Journal of Applied Genetics · doi:10.1007/s13353-023-00824-1 · Cited by 24
Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration
Cooper, D. J., Zunino, G., Bixby, J. L., & Lemmon, V. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.07.001 · Cited by 24
Ubiquitination and E3 Ubiquitin Ligases in Rare Neurological Diseases with Comorbid Epilepsy
Zhu, J., & Tsai, N. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.030 · Cited by 24
Therapeutic approaches for shankopathies
Wang, X., Bey, A. L., Chung, L., Krystal, A. D., & Jiang, Y. (2013) · Developmental Neurobiology · doi:10.1002/dneu.22084 · Cited by 23
Abnormalities of the DNA Methylation Mark and Its Machinery: An Emerging Cause of Neurologic Dysfunction
Weissman, J., Naidu, S., & Bjornsson, H. T. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1386763 · Cited by 22
Behavioral Evaluation of Angelman Syndrome Mice at Older Ages
Dutta, R., & Crawley, J. N. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.10.027 · Cited by 22
Molecular Evolution, Neurodevelopmental Roles and Clinical Significance of HECT-Type UBE3 E3 Ubiquitin Ligases
Ambrozkiewicz, M. C., Cuthill, K. J., Harnett, D., Kawabe, H., & Tarabykin, V. S. (2020) · Cells · doi:10.3390/cells9112455 · Cited by 21
Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome
Jamal, I., Kumar, V., Vatsa, N., Shekhar, S., Singh, B. K., Sharma, A., & Jana, N. R. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.010 · Cited by 22
Pharmacological Reactivation of the Silenced FMR1 Gene as a Targeted Therapeutic Approach for Fragile X Syndrome
Kumari, D., Gazy, I., & Usdin, K. (2019) · Brain Sciences · doi:10.3390/brainsci9020039 · Cited by 21
AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndrome
Campbell, A., Morris, G., Sanfeliu, A., Augusto, J., Langa, E., Kesavan, J., Nguyen, T. N., Conroy, R. M., Worm, J., Kielpinski, L. J., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.009 · Cited by 22

Authors: Huang, H.-S., Allen, J. A., Mabb, A. M., King, I. F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J. W., Lee, H.-M., Chen, X., Jin, J., Bridges, A. S., Zylka, M. J., Roth, B. L., & Philpot, B. D.
Affiliations: University of North Carolina at Chapel Hill (US)
Corresponding author: Zylka, Mark J.
Roth, Bryan L.
Philpot, Benjamin D.
ORCID: Huang, Hsien-Sung
Allen, John A.
Mabb, Angela M.
King, Ian F.
Miriyala, Jayalakshmi
Lee, Hyeong-Min
Chen, Xin
Jin, Jian
Zylka, Mark J.
Roth, Bryan L.
Philpot, Benjamin D.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2011-12-21
Volume: 481
Issue: 7380
Pages: 185-189
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10726
PMC: PMC3257422
OpenAlex: W2016365513
Cited by: 387
References: 38
Citations by year: 2026: 15 · 2025: 19 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 15 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 33 · 2016: 37 · 2015: 34 · 2014: 38 · 2013: 35 · 2012: 26
FWCI: 20.15
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: U.S. Public Health Service (HHSN-271-2008-00025-C)
National Institute of Mental Health (R01MH093372)
National Eye Institute (R01EY018323)
National Institute of Neurological Disorders and Stroke (R01NS060725, R01NS067688, P30NS045892, F32NS067712)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30-HD03110, P30HD003110, T32HD040127)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: Angelman syndrome, UBE3A, genomic imprinting, topoisomerase inhibitors, topotecan, epigenetic silencing, antisense RNA, cortical neurons, irinotecan, etoposide, dexrazoxane, drug repurposing, long-term drug effects
MeSH terms: Alleles, Animals, Cells, Cultured, Cerebral Cortex, Drug Evaluation, Preclinical, Fathers, Female, Male, Mice, Inbred C57BL, Mothers, Neurons, Angelman Syndrome, Genomic Imprinting, Topotecan, Gene Silencing, Ubiquitin-Protein Ligases, Mice, Small Molecule Libraries, Topoisomerase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks